Achmea Investment Management B.V. Cuts Position in CVS Health Co. (NYSE:CVS)

Achmea Investment Management B.V. cut its stake in CVS Health Co. (NYSE:CVS) by 10.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 106,143 shares of the pharmacy operator’s stock after selling 13,017 shares during the quarter. Achmea Investment Management B.V.’s holdings in CVS Health were worth $4,764,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in CVS. Versor Investments LP acquired a new stake in shares of CVS Health in the 3rd quarter worth $371,000. GSA Capital Partners LLP acquired a new stake in shares of CVS Health in the 3rd quarter worth $816,000. Aptus Capital Advisors LLC boosted its position in shares of CVS Health by 7.7% in the 3rd quarter. Aptus Capital Advisors LLC now owns 12,078 shares of the pharmacy operator’s stock worth $759,000 after purchasing an additional 865 shares in the last quarter. MQS Management LLC acquired a new stake in shares of CVS Health in the 3rd quarter worth $237,000. Finally, Oppenheimer & Co. Inc. lifted its position in CVS Health by 5.6% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 99,848 shares of the pharmacy operator’s stock worth $6,278,000 after acquiring an additional 5,325 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, SVP James David Clark sold 7,513 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael F. Mahoney purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. The trade was a 320.65 % increase in their position. The disclosure for this purchase can be found here. 0.24% of the stock is owned by company insiders.

CVS Health Price Performance

Shares of CVS Health stock opened at $65.63 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $80.75. The business has a 50-day moving average price of $58.47 and a 200 day moving average price of $57.00. The firm has a market cap of $82.75 billion, a PE ratio of 17.93, a P/E/G ratio of 0.98 and a beta of 0.53.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Sell-side analysts predict that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.05%. CVS Health’s dividend payout ratio (DPR) is currently 72.68%.

Analyst Upgrades and Downgrades

CVS has been the subject of a number of research reports. Leerink Partnrs raised CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 12th. Edward Jones raised CVS Health from a “hold” rating to a “buy” rating in a research report on Thursday, January 30th. JPMorgan Chase & Co. lifted their price target on CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 18th. Cantor Fitzgerald raised CVS Health from a “neutral” rating to an “overweight” rating in a research report on Wednesday, February 12th. Finally, TD Cowen lifted their price target on CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $69.83.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.